Retroperitoneal liposarcoma is a rare malignant tumor originating from the adipose tissue located behind the abdominal cavity. It is classified as one of the subtypes of liposarcoma and is characterized by an aggressive course, a tendency to relapse and metastasis. Retroperitoneal liposarcoma can develop in various places, including the renal area, retroperitoneal space and around large vessels. Clinical manifestations of the disease can vary depending on the location and size of the tumor, but the main symptoms are abdominal pain, a feeling of heaviness, and dyspeptic disorders. The prognosis for retroperitoneal liposarcoma depends on the stage of the disease, the morphological characteristics of the tumor and the success of treatment.
History of the disease and interesting historical facts
Liposarcoma, including the retroperitoneal form, was first described in the medical literature in the late 19th century. In 1874, John Houston defined the disease as a tumor arising from adipose tissue. The initial classification of soft tissue tumors was fairly simple and did not take into account the many subtypes. Interest in soft tissue sarcoma research increased in the 1940s and 1950s, when surgeons and pathologists began to distinguish different types and subtypes of liposarcomas. Since then, significant advances in molecular biology and histopathology have allowed for a more in-depth study of the biology of retroperitoneal liposarcoma, including molecular markers and prognosis.
Epidemiology
Retroperitoneal liposarcoma is a rare soft tissue tumor. Studies have shown that retroperitoneal sarcomas account for approximately 10-15% of all liposarcoma cases. The incidence of retroperitoneal liposarcoma varies, but it is estimated that there are 0.5 to 2 cases per million population per year. Patients are most often between 40 and 70 years of age, although younger cases have been reported. Comparatively more cases are observed in men than in women, which may be due to differences in lifestyle and environmental factors. It is important to note that retroperitoneal liposarcoma is observed in both developed and developing countries, highlighting the universality of the problem.
Genetic predisposition to this disease
Studies of genetic predisposition to retroperitoneal liposarcoma indicate the presence of certain mutations associated with the development of this disease. Some of the most studied genes are TP53, MDM2 and CDK4. Mutations in the TP53 gene, which is responsible for the regulation of the cell cycle and apoptosis, can lead to a loss of control over the proliferation of fat cells. The MDM2 gene acts as an inhibitor of TP53, and its amplification is observed in some patients with liposarcomas. Mutations in the CDK4 gene are also associated with impaired regulation of cell division and are found in some types of soft tissue tumors, including liposarcomas. In addition, there is evidence that polymorphisms in chemical metabolism genes affect predisposition to malignant neoplasms.
Risk factors for the development of this disease
Risk factors that contribute to the development of retroperitoneal liposarcoma can be divided into physical and chemical. Physical factors include:
- Age: The risk of developing cancer increases with age.
- Gender: Men are at higher risk.
- Soft tissue injuries: Injuries suffered at a young age can contribute to the development of tumors.
Chemical factors include:
- Working with chemical carcinogens: for example, benzene and various solvents.
- Occupational exposure: working in industrial environments with high levels of pollution.
- Smoking: Tobacco is known to be a factor that increases the risk of various malignant tumors.
Additionally, it is noted that the presence of comorbidities such as obesity and previous malignancies may increase the risk.
Diagnosis of this disease
Diagnosis of retroperitoneal liposarcoma requires a comprehensive approach, including both clinical and laboratory methods. The main symptoms indicating the possibility of this disease are:
- Pain in the abdominal area.
- Swelling or bulging in the abdominal area.
- Dyspeptic disorders such as nausea or indigestion.
Laboratory tests may include:
- Complete blood count: possible changes in indicators, such as anemia or leukocytosis.
- Blood biochemistry: assessment of liver and kidney function.
- Marker studies for the presence of specific tumor markers.
Radiological examinations such as ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) play a key role in visualizing the tumor and assessing its size and extent. Other diagnostics may include a biopsy for histological analysis.
The differential diagnosis should include other possible malignant and benign tumors of the abdominal cavity, such as neuroblastoma, lymphoma and other types of sarcomas.
Treatment
Treatment of retroperitoneal liposarcoma is a multi-stage process and typically includes surgery, chemotherapy and/or radiotherapy. The mainstay of treatment is surgical resection of the tumor, which, if possible, should be radical and include not only the tumor itself but also the surrounding tissues to reduce the risk of recurrence.
Pharmacological treatment, including chemotherapy, is often used when the tumor is metastatic or inoperable. Drugs such as docetaxel, adriamycin, and ifosfamide have shown efficacy in treating tumors of varying size.
Other treatments, such as radiotherapy, may be recommended for adjuvant therapy to reduce the risk of recurrence and to kill residual tumor cells after surgery. Immunotherapy is also being considered in some clinical trials as an option for treating advanced disease.
List of medications used to treat this disease
- Docetaxel (Taxotere)
- Adriamycin (doxorubicin)
- Ifosfamide
- Paclitaxel
- Epirubicin
Disease monitoring
Monitoring of retroperitoneal liposarcoma includes regular examinations and laboratory tests to assess the response to treatment and detect possible recurrence. Prognosis may vary depending on the stage at diagnosis, as well as the morphological characteristics of the tumor. Complications may arise from the tumor itself or from treatment, such as infections after surgery or side effects of chemotherapy.
Age-related features of the disease
Retroperitoneal liposarcoma is most often observed in people aged 40 to 70 years. In children, this disease is extremely rare, but there is an increased predisposition to the development of soft tissue tumors in childhood in the presence of hereditary syndromes, such as Li-Fraumeni syndrome. In older people, the disease may be preceded by many concomitant pathologies, which complicates diagnosis and treatment.
Questions and Answers
- What are the main symptoms of retroperitoneal liposarcoma? The main symptoms are abdominal pain, discomfort, loss of appetite and dyspeptic disorders.
- What is the treatment for retroperitoneal liposarcoma? Treatment includes surgical resection of the tumor, chemotherapy and radiotherapy, depending on the stage of the disease.
- How is retroperitoneal liposarcoma diagnosed? The main diagnostic methods include ultrasound, CT and MRI, as well as laboratory blood tests and tumor biopsy.
- What is the predisposition to this disease? The risk of increased retroperitoneal liposarcoma is associated with factors such as age, gender, trauma, and exposure to chemical carcinogens.
- What is the prognosis for patients with retroperitoneal liposarcoma? The prognosis depends on the stage of the disease at the time of diagnosis, the morphology of the tumor and the success of treatment; early detection of the disease is extremely important.
